Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer

Radiotherapy and Oncology

Volumn 107, Issue 2, 2013, Pages 123-128

  Denham, James W ^a   Steigler, Allison ^a   Tai, Keen Hun ^b   Joseph, David ^c   Matthews, John ^d   Atkinson, Chris ^e   Spry, Nigel A ^c   Turner, Sandra ^f   North, John ^g   Christie, David ^h   Wynne, Chris ^e   Lamb, David S ⁱ  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^d AUCKLAND CITY HOSPITAL   (New Zealand)

^e St Georges Cancer Care Centre   (New Zealand)

^f WESTMEAD HOSPITAL   (Australia)

^g DUNEDIN HOSPITAL   (New Zealand)

^h Premion Cancer Care ^*  (Australia)

ⁱ WELLINGTON HOSPITAL   (New Zealand)

Author keywords

Androgen suppression; Metastatic progression; Prostate cancer; Radiotherapy

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER STAGING; CONTROLLED STUDY; DISTANT METASTASIS; FOLLOW UP; HUMAN; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT DURATION;

ANDROGEN ANTAGONISTS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84879022325     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2013.03.025     Document Type: Article

References (21)

1. M.V. Pilepich, K. Winter, and M.J. John Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252 (Pubitemid 32727802)
2. J.W. Denham, A. Steigler, and D.S. Lamb Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial Lancet Oncol 6 2005 841 850 (Pubitemid 41614795)
3. J.W. Denham, D.S. Lamb, and D. Joseph PSA response signatures - a powerful new prognostic indicator after radiation for prostate cancer? Radiother Oncol 90 2009 382 388
4. J.P. Fine, and R.J. Gray A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 1999 496 509
5. K.M.G. Haustermans, I. Hofland, and H. van Poppel Cell kinetic measurements in prostate cancer Int J Radiat Oncol Biol Phys 37 1997 1067 1070 (Pubitemid 27237722)
6. J.S. Meyer, G. Sufrin, and S.A. Martin Proliferative activity of benign human prostate, prostatic adenocarcinoma and seminal vesicle evaluated by thymidine labeling J Urol 128 1982 1353 1356 (Pubitemid 13191033)
7. R. Nemoto, K. Hattori, and K. Uchida S-phase fraction of human prostate adenocarcinoma studied with in vivo bromodeoxyuridine labeling Cancer 66 1990 509 514 (Pubitemid 20233449)
8. E.E.R. Harris, Y.T. Hwang, F. Seyednejad, and L.J. Solin Prognosis after regional lymph node recurrence in patients with stage I-II breast carcinoma treated with breast conservation therapy Cancer 98 2003 21 44
9. R.R. Berges, J. Vukanovic, and J.I. Epstein Implication of cell kinetic changes during the progression of human prostatic cancer Clin Cancer Res 1 1995 473 480
10. P.B. Morgan, A.L. Hanlon, E.M. Horwitz, M.K. Buyyounouski, R.G. Uzzo, and A. Pollack Radiation dose and late failures in prostate cancer Int J Radiat Oncol Biol Phys 67 2007 1074 1081
11. M.J. Zelefsky, L. Ben-Porat, and H.I. Scher Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer J Clin Oncol 23 2005 826 831 (Pubitemid 46224182)
12. A.T. Bates, T. Pickles, and C. Paltiel PSA doubling time kinetics during prostate cancer biochemical relapse after external beam radiation therapy Int J Radiat Oncol Biol Phys 62 2005 148 153 (Pubitemid 40591936)
13. F. Rabbani, M. Perrotti, A. Bastar, and W.R. Fair Prostate specific antigen doubling time after radical prostatectomy: effect of neoadjuvant androgen deprivation therapy J Urol 161 1999 847 852 (Pubitemid 29422381)
14. J.W. Denham, A. Steigler, and D.S. Lamb Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial Lancet Oncol 12 2011 451 459
15. M. Bolla, T.M. De Reijke, and G. van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
16. E.M. Horwitz, K. Bae, and G.E. Hanks Ten-year follow-up of Radiation Therapy Oncology Group Protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J Clin Oncol 26 2008 2497 2504
17. A.V. D'Amico, M.-H. Chen, A.A. Renshaw, M. Loffredo, and P.W. Kantoff Androgen suppression and radiation vs radiation alone for prostate cancer JAMA 299 2008 289 295 (Pubitemid 351159365)
18. J. Laverdiere, J.L. Gomez, and L. Cusan Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer Int J Radiat Oncol Biol Phys 37 1997 247 252 (Pubitemid 27138705)
19. J. Crook, C. Ludgate, and S. Malone Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer Int J Radiat Oncol Biol Phys 60 2004 15 23 (Pubitemid 39165464)
20. C.U. Jones, D. Hunt, and D.G. McGowan Radiotherapy and short-term androgen deprivation for localized prostate cancer N Engl J Med 365 2011 107 118
21. J.W. Denham, D.S. Lamb, and D. Joseph Another form of subgroup to beware Radiother Oncol 101 2011 525 526